Abbott Laboratories (ABT) narrows 2024 earnings guidance, shares slip
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Abbott Labs (ABT) PT Lowered to $125 at RBC Capital
April 18, 2024 6:19 AM EDTRBC Capital analyst Shagun Singh lowered the price target on Abbott Labs (NYSE: ABT) to $125.00 (from $128.00) while maintaining a Outperform rating.
The analyst comments "ABT delivered a Q1 Rev/EPS upside of $80MM/$0.03, respectively, and tightened its FY24 guidance range. Despite a strong Q1... More
Abbott's device sales drive profit beat, but shares fall as forecast disappoints
April 17, 2024 7:34 AM EDTBy Leroy Leo and Pratik Jain
(Reuters) -Abbott Laboratories beat Wall Street estimates for quarterly profit on Wednesday on robust sales of its medical devices, but the company's stock fell 3% in morning trading, signaling disappointment over its annual forecast.
Investor expectations around the performance of medical device makers have been heightened since last November after a resurgence in demand, as people, especially older adults, opted for medical procedures deferred during the pandemic.
Abbott forecast a full-year profit of... More
